Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 2:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,317 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: positron emission tomography Clear all
Completed No phase listed Observational

PET Imaging of Nicotinic Acetylcholine Receptors

NCT01046513
View directory record Official record
Conditions
Healthy Volunteers, Nicotine Dependence, Pharmacokinetics
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 12, 2026, 2:54 AM EDT
Recruiting Phase 1 Interventional

First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging

NCT05335811
View directory record Official record
Conditions
Endocrine Neoplasia
Interventions
4-[18F]Fluoro-1-Naphthol
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 12, 2026, 2:54 AM EDT
Completed Early Phase 1 Interventional

Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective

NCT01873248
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
68Ga-DOTATATE
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Sep 12, 2026, 2:54 AM EDT
Completed Phase 2Phase 3 Interventional Results available

68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer

NCT02624518
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
68Ga-RM2, Magnetic Resonance Imaging, Positron Emission Tomography
Drug · Procedure
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older · Male only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Sep 12, 2026, 2:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Cannabinoid CB1 Receptors Using [11C]MePPEP

NCT00598390
View directory record Official record
Conditions
Healthy
Interventions
[11C]MePPEP
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Sep 12, 2026, 2:54 AM EDT
Recruiting Phase 1 Interventional

FAPI-74 PET/CT in Adults With Fibrosis

NCT06413355
View directory record Official record
Conditions
Fibrosis (Morphologic Abnormality)
Interventions
[F-18]-FAPI-74
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 12, 2026, 2:54 AM EDT
Completed Phase 2 Interventional Results available

New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

NCT00001849
View directory record Official record
Conditions
Cushing Syndrome, Endocrine Disease
Interventions
Pentetreotide, 18F-DOPA, CT scan, MRI, 18-FDG
Drug · Device
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 90 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 12, 2026, 2:54 AM EDT
Recruiting Phase 4 Interventional

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

NCT07569926
View directory record Official record
Conditions
Prostate Cancer
Interventions
fluciclovine (18F)
Drug
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years and older · Male only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
San Diego, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 12, 2026, 2:54 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

NCT03952585
View directory record Official record
Conditions
Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
493
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 348 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 12, 2026, 2:54 AM EDT
Completed Not applicable Interventional

Total-Body FDG PET for Radiotherapy Response Assessment in Head and Neck Cancer

NCT05625217
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Total Body PET/CT Imagin
Diagnostic Test
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 12, 2026, 2:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of EVP-6308 to Assess the Dose- and Concentration-dependent Displacement of [18F]MNI-659 by EVP-6308

NCT02001389
View directory record Official record
Conditions
Healthy
Interventions
EVP-6308
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Sep 12, 2026, 2:54 AM EDT
Withdrawn Not applicable Interventional

Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers

NCT01360177
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
124 PET/CT imaging, Na134I, Tri-iodothyronine
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Sep 12, 2026, 2:54 AM EDT
Active, not recruiting Not applicable Interventional Results available

PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer

NCT01737619
View directory record Official record
Conditions
Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma, Grade 3 Endometrial Endometrioid Adenocarcinoma, Malignant Mixed Mesodermal (Mullerian) Tumor
Interventions
Computed Tomography, Indocyanine Green Solution, Laboratory Biomarker Analysis, Lymph Node Mapping, Lymphadenectomy, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
7
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 12, 2026, 2:54 AM EDT
Active, not recruiting Early Phase 1 Interventional

Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors

NCT03335670
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
[68Ga]Pentixafor
Drug
Lead sponsor
Yusuf Menda
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 12, 2026, 2:54 AM EDT
Recruiting Not applicable Interventional

Imaging Metabolic and Perfusion Changes in Acupuncture Therapy for Myofascial Pain Syndrome

NCT07494162
View directory record Official record
Conditions
Myofascial Pain Syndrome (MPS), Chronic Low-back Pain (cLBP)
Interventions
Acupuncture, Sham Acupuncture, Total-Body PET/CT Imaging
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 12, 2026, 2:54 AM EDT
Completed Phase 1 Interventional Results available

Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response

NCT00694096
View directory record Official record
Conditions
Renal Cell Cancer
Interventions
Sunitinib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 30, 2015 · Synced Sep 12, 2026, 2:54 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Tau Imaging With JNJ067

NCT03926702
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Progressive Supranuclear Palsy
Interventions
Radiopharmaceuticals
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Sep 12, 2026, 2:54 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.

NCT07095205
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Nicotine transdermal patch, PET Scan with [18F] VAT
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 12, 2026, 2:54 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Imaging CRF X NOP Interactions in Alcohol Use Disorder

NCT07612631
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Baseline [C-11]NOP-1A PET scan, Hydrocortisone, Post-hydrocortisone [C-11]NOP-1A PET scan
Radiation · Drug
Lead sponsor
Rajesh Narendran
Other
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 12, 2026, 2:54 AM EDT
Not listed Phase 2 Interventional

Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

NCT00083083
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, docetaxel, etoposide, paclitaxel, vinblastine sulfate, vinorelbine tartrate, gene expression analysis, positron emission tomography, fludeoxyglucose F 18, radiation therapy
Drug · Genetic · Procedure + 1 more
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
46
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Sep 12, 2026, 2:54 AM EDT
Terminated Phase 3 Interventional

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

NCT01313572
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Apadenoson SPECT-MPI, Adenosine SPECT-MPI
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
45
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Sep 12, 2026, 2:54 AM EDT
Not listed Not applicable Interventional

Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)

NCT05823402
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
SPECT/CT
Diagnostic Test
Lead sponsor
BAMF Health
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 12, 2026, 2:54 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluation of [11C]ZTP-1 to Image PDE4B

NCT07625345
View directory record Official record
Conditions
Healthy
Interventions
11C-ZTP-1
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 101 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 12, 2026, 2:54 AM EDT
Not yet recruiting Phase 2 Interventional

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

NCT07612007
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Darizmetinib, Embolization Therapy, Hepatectomy, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 12, 2026, 2:54 AM EDT